

SUMMARY OF PRODUCT CHARACTERISTIC

SUMMARY OF PRODUCT CHARACTERISTIC (SPC)

1 NAME OF THE MEDICINAL PRODUCT

1.1 Name of the medicinal product

ODIMONT L

Montelukast and Levocetirizine Dihydrochloride Tablets 10mg/5mg

1.2 Strength

10mg/5mg

1.3 Pharmaceutical Form

Film coated tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains:

Montelukast Sodium Ph. Eur.

equivalent to Montelukast 10mg

Levocetirizine Dihydrochloride USP 5mg

Colors: Yellow Iron Oxide, Titanium Dioxide and Red Iron

Oxide
The product contains Lactose.

For full list excipient, see section 6.1

3 PHARMACEUTICAL FORM

Light yellow to yellow colored, round shaped, beveled edge, biconvex, film coated tablets, debossed with 'ML' on one side and plain on other sides.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS:

Montelukast and levocetirizine dihydrochloride tablets are indicated in adults and adolescents aged 15 years or older for the relief of symptoms associated with:

- Allergic Rhinitis

4.2 POSOLOGY AND METHOD OF ADMINISTRATION:

Posology:

The recommended dose of montelukast and levocetirizine dihydrochloride is one tablet of each once a day.

SUMMARY OF PRODUCT CHARACTERISTIC

Method of administration:

Oral use

The dose can be taken with or without food.

Not for administration in patients below 15 years of age.

4.3 CONTRAINDICATIONS:

Hypersensitivity to montelukast to levocetirizine dihydrochloride, to cetirizine, to hydroxyzine, to any other piperazine derivatives or to any of the other excipients.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE:

Montelukast and levocetirizine dihydrochloride tablets are not a treatment for Asthma. Montelukast and levocetirizine dihydrochloride tablets should not be prescribed for the treatment of asthma. However, it may be prescribed with other medications used for the management of asthma.

LEVOCETIRIZINE DIHYDROCHLORIDE:

Precaution is recommended with concurrent intake of alcohol. Caution should be taken in patients with predisposing factors of urinary retention (e.g., spinal cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention. Caution should be taken in patients with epilepsy and patients at risk of convulsion as levocetirizine may cause seizure aggravation.

Response to allergy skin tests is inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.

Pruritus may occur when levocetirizine is stopped even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.

MONTELUKAST:

Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled beta-agonist should be used. Patients should seek their doctor's advice as soon as possible if they need more inhalations of short-acting beta-agonists than usual.

Montelukast should not be substituted abruptly for inhaled or oral corticosteroids.

There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.

Neuropsychiatric events have been reported with montelukast. Instruct patients to be alert for neuropsychiatric events. Evaluate the risks and benefits of continuing

SUMMARY OF PRODUCT CHARACTERISTIC

treatment with montelukast if such events occur.

In rare cases, patients on therapy with montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.

Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.

This medicinal product contains lactose monohydrate.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

LEVOCETIRIZINE DIHYDROCHLORIDE:

No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, azithromycin, cimetidine, diazepam, erythromycin, glipizide, ketoconazole and pseudoephedrine). A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.

In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.

The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased.

In sensitive patients, the concurrent administration of cetirizine or levocetirizine and alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.

MONTELUKAST:

Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the

SUMMARY OF PRODUCT CHARACTERISTIC

recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/ norethindrone 35/1), terfenadine, digoxin and warfarin.

The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.

In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 in vivo. Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide.).

In vitro studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.

Based on in vitro data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.

4.6 PREGNANCY AND LACTATION

Pregnancy:

As a precautionary measure, it is preferable to avoid the use of levocetirizine and/or montelukast during pregnancy.

Breast-feeding:

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from levocetirizine / montelukast therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility:

There are no data available on male and female fertility.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES:

Some patients could experience somnolence, fatigue and asthenia under therapy with levocetirizine. As there is individual variation in response to all medicinal

SUMMARY OF PRODUCT CHARACTERISTIC

products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.

4.8 UNDESIRABLE EFFECTS

LEVOCETIRIZINE DIHYDROCHLORIDE:

Clinical studies:

In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.

In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo.

Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the medicinal product at the recommended dose of 5 mg daily. From this pooling, adverse drug reactions were reported at rates of 1% or greater (common: $\geq 1/100$ to $< 1/10$) following incidence of under levocetirizine 5 mg or placebo.

Preferred Term (WHOART)	Placebo (n =771)	Levocetirizine 5 mg (n = 935)
Headache	25 (3.2%)	24 (2.6%)
Somnolence	11 (1.4%)	49 (5.2%)
Mouth dry	12 (1.6%)	24 (2.6%)
Fatigue	9 (1.2%)	23 (2.5%)

Further uncommon incidences of adverse reactions $\geq 1/1,000$ to $< 1/100$) like (uncommon asthenia or abdominal pain were observed.

The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1%) under levocetirizine 5 mg than under placebo (3.1%).

Paediatric population:

In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25 mg daily for 2 weeks and 1.25 mg twice daily respectively.

The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.

SUMMARY OF PRODUCT CHARACTERISTIC

System Organ Class and Preferred Term	Placebo (n=83)	Levocetirizine (n=159)
Gastrointestinal disorders		
Diarrhoea	0	3(1.9%)
Vomiting	1(1.2%)	1(0.6%)
Constipation	0	2(1.3%)
Nervous system disorders		
Somnolence	2(2.4%)	3(1.9%)
Psychiatric disorders		
Sleep disorder	0	2(1.3%)

In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5 mg levocetirizine daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.

Preferred Term	Placebo (n=240)	Levocetirizine 5mg (n=243)
Gastrointestinal disorders		
Headache	5(2.1%)	2(0.8%)
Somnolence	1(0.4%)	7(2.9%)

Post-marketing experience:

Adverse reactions from post-marketing experience are per System Organ Class frequency. The frequency is defined as follows: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$), not known (cannot be estimated from the available data).

• Immune system disorders:

Not known: hypersensitivity including anaphylaxis

• Metabolism and nutrition disorders: Not known: increased appetite

• Psychiatric disorders:

Not known: aggression, agitation, hallucination, depression, insomnia, suicidal ideation, nightmare

• Nervous system disorders:

Not known: convulsion, paraesthesia, dizziness, syncope, tremor, dysgeusia

• Ear and labyrinth disorders: Not known: vertigo

• Eyes disorders:

Not known: visual disturbances, blurred vision

• Cardiac disorders:

Not known: palpitations, tachycardia

SUMMARY OF PRODUCT CHARACTERISTIC

- Respiratory, thoracic and mediastinal disorders: Not known: dyspnoea
 - Gastrointestinal disorders:
Not known: nausea, vomiting, diarrhoea
 - Hepatobiliary disorders: Not known: hepatitis
 - Renal and urinary disorders:
Not known: dysuria, urinary retention
 - Skin and subcutaneous tissue disorders:
Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria
 - Musculoskeletal, connective tissues, and bone disorders: Not known: myalgia, arthralgia
 - General disorders and administration site conditions: Not known: oedema
 - Investigations:
Not known: weight increased, abnormal liver function tests
- Description of selected adverse reactions:
After levocetirizine discontinuation, pruritus has been reported.

MONTELUKAST:

Tabulated list of Adverse Reactions:

Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Experience Term, in the table below. Frequency Categories were estimated based on relevant clinical trials.

System Organ Class	Adverse reactions seen with Montelukast	Frequency
Infections and infestations	upper respiratory infection [†]	Very Common
Blood and lymphatic system disorders	increased bleeding tendency	Rare
Immune system disorders	hypersensitivity reactions including anaphylaxis	Uncommon
	hepatic eosinophilic infiltration	Very Rare
Psychiatric disorders	dream abnormalities including nightmares, insomnia, somnambulism, irritability, anxiety, restlessness, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor [§])	Uncommon

SUMMARY OF PRODUCT CHARACTERISTIC

	disturbance in attention, memory impairment	Rare
	hallucinations, disorientation, suicidal thinking and behaviour (suicidality)	Very Rare
Nervous system disorder	dizziness, drowsiness, paraesthesia/hypoesthesia, seizure	Uncommon
Cardiac disorders	palpitations	Rare
Respiratory, thoracic and mediastinal disorders	Epistaxis	Uncommon
	Churg-Strauss Syndrome (CSS), eosinophilia, pulmonary	Very Rare
Gastrointestinal disorders	diarrhoea [‡] , vomiting [‡] , nausea [‡]	Common
	dry mouth, dyspepsia	Uncommon
Hepatobiliary disorders	elevated levels of serum transaminases (ALT, AST)	Common
	hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).	Very Rare
Skin and subcutaneous tissue disorders	rash [‡]	Common
	bruising, urticaria, pruritus	Uncommon
	angioedema	Rare
	erythema nodosum, erythema multiforme	Very Rare
Musculoskeletal, connective tissue and bone disorders	arthralgia, myalgia including	Uncommon
	muscle cramps	
General disorders and administration site conditions	pyrexia [‡]	Common
	asthenia/fatigue, malaise, oedema,	Uncommon

SUMMARY OF PRODUCT CHARACTERISTIC

*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common ($\geq 1/10$), Common ($\geq 1/100$ to $< 1/10$), Uncommon ($\geq 1/1000$ to $< 1/100$), Rare ($\geq 1/10,000$ to $< 1/1000$), Very Rare ($< 1/10,000$).

†This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.

‡This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.

§ Frequency Category: Rare

4.9 OVERDOSE

LEVOCETIRIZINE DIHYDROCHLORIDE:

Symptoms of overdose:

Symptoms of overdose may include drowsiness in adults. In children, agitation and restlessness may initially occur, followed by drowsiness.

Management of overdoses:

There is no known specific antidote to levocetirizine.

Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage may be considered shortly after ingestion of the drug. Levocetirizine is not effectively removed by haemodialysis.

MONTELUKAST:

There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1000 mg (approximately 61 mg/kg in a 42-month-old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients.

Symptoms of overdose:

There were no adverse experiences in the majority of overdose reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity.

Management of overdose:

No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.

5. PHARMACOLOGICAL PROPERTIES:

LEVOCETIRIZINE DIHYDROCHLORIDE:

5.1 Pharmacodynamic properties:

SUMMARY OF PRODUCT CHARACTERISTIC

Pharmacotherapeutic group: antihistamine for systemic use, piperazine derivatives,

ATC code: R06A E09.

Mechanism of action:

Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H₁-receptors.

Binding studies revealed that levocetirizine has high affinity for human H₁-receptors (K_i = 3.2 nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (K_i = 6.3 nmol/l). Levocetirizine dissociates from H₁-receptors with a half-life of 115 ± 38 min. After single administration, levocetirizine shows receptor occupancy of 90% at 4 hours and 57% at 24 hours.

Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.

Pharmacodynamics effects:

The pharmacodynamic activity of levocetirizine has been studied in randomised, controlled trials:

In a study comparing the effects of levocetirizine 5 mg, desloratadine 5 mg, and placebo on histamine-induced wheal and flare, levocetirizine treatment resulted in significantly decreased wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours, (p < 0.001) compared with placebo and desloratadine.

The onset of action of levocetirizine 5 mg in controlling pollen-induced symptoms has been observed at 1 hour post drug intake in placebo-controlled trials in the model of the allergen challenge chamber.

In vitro studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study in vivo (skin chamber technique) showed three main inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 releases, modulation of vascular permeability and a decrease in eosinophil recruitment.

Clinical efficacy and safety:

The efficacy and safety of levocetirizine has been demonstrated in several double-blind, placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies.

A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, levocetirizine significantly improved the quality of life of the patients.

In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with

SUMMARY OF PRODUCT CHARACTERISTIC

levocetirizine 5 mg oncedaily over six weeks.

Treatment with levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology LifeQuality Index as compared to placebo.

Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histaminerelease is a causal factor in urticarial diseases, levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathicurticaria.

ECGs did not show relevant effects of levocetirizine on QT interval.Paediatric population:

The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved symptoms and increased health- related quality of life.

In children below the age of 6 years, clinical safety has been established from several short-or long -term therapeutic studies:

- one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treatedwith levocetirizine 1.25 mg twice daily for 4 weeks
- one clinical trial in which 114 children 1 to 5 years of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg twice daily for 2 weeks
- one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronicidiopathic urticaria were treated with levocetirizine 1.25 mg once daily for 2 weeks one long-term (18 months) clinical trial in 255 levocetirizine - treated atopic subjects aged12 to 24 months at inclusion.

The safety profile was similar to that seen in the short-term studies conducted in children 1 to5 years of age.

5.2 Pharmacokinetic properties:

The pharmacokinetics of levocetirizine are linear with dose- and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination.

Absorption:

Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after twodays. Peak concentrations are typically 270 ng/ml and 308 ng/ml following a single and a repeated 5 mg o.d. dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.

Distribution:

SUMMARY OF PRODUCT CHARACTERISTIC

No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the bloodbrain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment.

In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg.

Biotransformation:

The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose.

Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely.

Elimination:

The plasma half-life in adults is 7.9 ± 1.9 hours. The half-life is shorter in small children. The mean apparent total body clearance in adults is 0.63 ml/min/kg. The major route of excretion of levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.

Special population:

Renal impairment:

The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of levocetirizine removed during a standard 4-hour hemodialysis procedure was < 10%.

Paediatric population:

Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that C_{max} and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean C_{max} was 450 ng/ml, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and

SUMMARY OF PRODUCT CHARACTERISTIC

124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily.

Elderly:

Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65–74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose should be adjusted in accordance with renal function in elderly patients.

Gender:

Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 ± 1.72 hr) than in men (8.62 ± 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 ± 0.16 ml/min/kg) appears to be comparable to that in men (0.59 ± 0.12 ml/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.

Race:

The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.

Hepatic impairment:

The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half-life along with a 40% decrease in clearance compared to healthy subjects.

Pharmacokinetic / pharmacodynamic relationship:

The action on histamine-induced skin reactions is out of phase with the plasma concentrations.

5.3 Preclinical safety data:

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

SUMMARY OF PRODUCT CHARACTERISTIC

MONTELUKAST:

5.1 Pharmacodynamic properties:

Pharmacotherapeutic group: Leukotriene receptor

antagonistATC code: R03D C03

Mechanism of action:

In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis.

Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.

Clinical efficacy and safety:

A clinical study was conducted to evaluate montelukast for the symptomatic treatment of seasonal allergic rhinitis in adult and adolescent asthmatic patients 15 years of age and older with concomitant seasonal allergic rhinitis. In this study, montelukast 10 mg tablets administered once daily demonstrated a statistically significant improvement in the Daily Rhinitis Symptoms score, compared with placebo. The Daily Rhinitis Symptoms score is the average of the Daytime Nasal Symptoms score (mean of nasal congestion, rhinorrhea, sneezing, nasal itching) and the Nighttime Symptoms score (mean of nasal congestion upon awakening, difficulty going to sleep, and nighttime awakenings scores). Global evaluations of allergic rhinitis by patients and physicians were significantly improved, compared with placebo. The evaluation of asthma efficacy was not a primary objective in this study.

5.2 Pharmacokinetic properties:

Absorption:

Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C_{max}) is achieved 3 hours (T_{max}) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C_{max} are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.

Distribution:

Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.

Biotransformation:

Montelukast is extensively metabolised. In studies with therapeutic doses, plasma

SUMMARY OF PRODUCT CHARACTERISTIC

concentrations of metabolites of montelukast are undetectable at steady state in adults and children.

Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on *in vitro* results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.

Elimination:

The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and <0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.

Characteristics in patients:

No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score >9).

With high doses of montelukast (20- and 60-fold the recommended adult dose), decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.

5.3 Preclinical safety data:

In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided >17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (>232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (>69fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure >24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.

SUMMARY OF PRODUCT CHARACTERISTIC

No deaths occurred following a single oral administration of montelukast sodium at doses up to 5000 mg/kg in mice and rats (15,000 mg/m² and 30,000 mg/m² in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).

Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately >200-fold based on systemic exposure). Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients:

Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Hydroxypropyl Cellulose, Magnesium Stearate, Opadry Yellow 20A82772 (Hypromellose, Hydroxypropyl Cellulose, Titanium Dioxide, Iron Oxide Yellow, Iron Oxide Red)

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

DO NOT STORE ABOVE 30°C.
KEEP OUT OF REACH OF CHILDREN.

6.5 Nature and contents of container

Alu-Alu Blister Pack of 10's

6.6 Special precautions for disposal and other handling

Any unused product or waste material should be disposed of in accordance with local requirements.

7. REGISTRANT

Marketing Authorization holder
Cadila Healthcare Limited
Zydus Tower, Satellite Cross Roads,
Ahmedabad 380 015,

SUMMARY OF PRODUCT CHARACTERISTIC

India.

Tel. No. : +91-79-2686 8100 (20 lines)

Fax No. : +91-79-2686 2365 / 66

MANUFACTURER

Cadila Healthcare Limited

Kundaim Industrial Estate, Plot No. 203-213,

Kundaim, Goa - 403 115, **India.**

Tel. No. : +91-832-6615401/6615123/6615124

Fax No. : +91-832-2395203

8. MARKETING AUTHORIZATION NUMBER: TAN 21 HM 0224

9. DATE OF FIRST AUTHORIZATION: 3rd June, 2021

10. DATE OF REVISION OF THE TEXT

To be included after first registration.